The case for & against
Bull & Bear analysis
Bullish
Pharming Group N.V. (NASDAQ: PHAR) operates in the biopharmaceutical industry, focusing on therapies for rare diseases such as Hereditary Angioedema (HAE) and Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS). The company is positioning itself with significant market potential through its innovative products, predominantly Ruconest and Joenja, while also advancing a promising pipeline aimed at immunology and pediatric indications. With a notable transition towards international market expansion and strong momentum in existing therapies, Pharming is expected to be a major player in addressing critical unmet medical needs.
Bull says
- ↑Ruconest saw 49% YoY growth, fueling robust top-line momentum.
- ↑Joenja revenue rose 34% YoY to $14.1M, diversifying sales mix.
- ↑2026 revenue guidance of $405–$425M implies 8–13% YoY growth.
- ↑FDA acceptance of Joenja pediatric sNDA could unlock new patient base.
- ↑Q1 operating cash flow of $2M and strong balance sheet support R&D expansion.
- ↑Strong growth and profitability factors underpin durable long-term upside.
Bear says
- ↓Q1 revenue declined 8% YoY to $72.4M amid inventory normalization.
- ↓Ruconest market share pressured by new HAE treatment entrants.
- ↓Inventory drawdowns introduce volatility in quarterly revenue forecasts.
- ↓Analyst revisions trending down signal reduced growth expectations.
- ↓High short interest and low institutional ownership reflect skepticism.
- ↓Negative earnings yield suggests limited near-term return potential.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-14-2026bullish
Transcript signals
Bull points
- we expect roughly 75, 76% of our pricing action to flow through to the net line this year.
- we've continued to build the funnel. Now, and we've seen an acceleration as both Fabrice and I mentioned earlier in the call in patients coming on to paid therapy in Q1, which was really nice to see.
- Q1 was a very strong quarter for farming. The revenues grew by 42%, driven by Ruconest growth of 49% and Joengia by 9% versus Q1 last year.
Bear points
- So the high tax cost that we had in Q1 is a one-off, and we don't expect that to continue in the remainder of the year.
- The net loss was $14.9 million, and that increased loss was primarily due to the non-recurring Abliva acquisition-related expenses, most of which were non-tax deductible.
- The cash and marketable securities decreased since the end of the 2024 by 60.5 million to 108.9 million. And that was primarily driven by the purchase of the Abliva shares totaling 66.1 million dollars.
Read full transcript analysis ›